Masanari Kodera

机构：Chukyo Hospital

发表论文 89 篇 · 总被引 3141 次 · h-index 23

代表论文

• Efficacy and safety of nemolizumab in paediatric patients aged 6–12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study (2023 · British Journal of Dermatology · 被引 49)
• GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region (2024 · Nature Communications · 被引 18)
• B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment (2025 · Annals of the Rheumatic Diseases · 被引 10)
• POS0120 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED MONTHLY OVER 28 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (2023 · Annals of the Rheumatic Diseases · 被引 9)
• Wound, Pressure Ulcer, and Burn Guidelines‐5: Guidelines for the management of lower leg ulcers and varicose veins, second edition (2024 · The Journal of Dermatology · 被引 5)
• OP0089 PHASE 2 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED EVERY 4 WEEKS UP TO 48 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) (2024 · Annals of the Rheumatic Diseases · 被引 5)